IRIS
SIGHINOLFI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.461
EU - Europa 706
AS - Asia 157
Continente sconosciuto - Info sul continente non disponibili 4
Totale 2.328
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.461
PL - Polonia 555
CN - Cina 102
IT - Italia 77
VN - Vietnam 52
GB - Regno Unito 25
DE - Germania 21
SE - Svezia 19
NL - Olanda 4
EU - Europa 3
FR - Francia 2
UA - Ucraina 2
AP - ???statistics.table.value.countryCode.AP??? 1
IN - India 1
IQ - Iraq 1
RO - Romania 1
TR - Turchia 1
Totale 2.328
Salva come PNG Salva come JPEG
Città #
Warsaw 555
Fairfield 328
Woodbridge 143
Seattle 126
Houston 115
Wilmington 111
Ashburn 108
Cambridge 95
Chandler 93
Beijing 88
Dong Ket 52
Princeton 46
Ann Arbor 35
San Diego 33
Bremen 20
Ferrara 19
Santa Maria Di Sala 14
London 13
Bologna 9
Falls Church 9
Redwood City 9
Addison 4
Chiswick 4
Jacksonville 4
Milan 4
Norwalk 4
Rome 4
Chicago 3
Cordenons 3
Mountain View 3
North Wales 3
Wuhan 3
Des Moines 2
Haikou 2
Jinan 2
Teulada 2
Tianjin 2
Verolanuova 2
Baghdad 1
Boardman 1
Buffalo 1
Castel Guelfo di Bologna 1
Gurgaon 1
Izmir 1
Jiaxing 1
Kansas City 1
Kunming 1
Lentate Sul Seveso 1
Mesagne 1
Miami Beach 1
Nanjing 1
New Bedfont 1
Shanghai 1
Somma Lombardo 1
Stockholm 1
Tappahannock 1
Zhengzhou 1
Totale 2.091
Salva come PNG Salva come JPEG
Nome #
Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation 100
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 89
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 82
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 72
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 71
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 68
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 67
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 65
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 65
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 63
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 63
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 62
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 62
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 62
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 60
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 59
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 59
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 57
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 57
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 56
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 56
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 56
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 56
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 54
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 54
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 52
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 52
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 51
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 51
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 50
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 49
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 49
A Comparison Between Different Anti-Retroviral Therapy Regimes on Soluble Inflammation Markers: a Pilot Study 49
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 48
null 46
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 45
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 45
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 44
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? 41
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 40
CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period. 39
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 35
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 35
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 30
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 16
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 6
Totale 2.488
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201921 0 0 0 2 0 1 2 0 1 6 4 5
2019/2020418 5 1 1 6 2 2 4 2 170 125 39 61
2020/20211.404 8 88 57 233 208 178 142 118 76 181 18 97
2021/2022332 39 19 2 5 14 39 21 28 15 39 12 99
2022/2023261 47 11 10 10 46 25 10 38 33 2 19 10
2023/202447 13 25 9 0 0 0 0 0 0 0 0 0
Totale 2.488